BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 32515349)

  • 21. Variant BMP receptor mutations causing fibrodysplasia ossificans progressiva (FOP) in humans show BMP ligand-independent receptor activation in zebrafish.
    Mucha BE; Hashiguchi M; Zinski J; Shore EM; Mullins MC
    Bone; 2018 Apr; 109():225-231. PubMed ID: 29307777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Twists in the fibrodysplasia ossificans progressiva story challenge and expand our understanding of BMP biology.
    Collins MT
    J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35703179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ACVR1 Function in Health and Disease.
    Valer JA; Sánchez-de-Diego C; Pimenta-Lopes C; Rosa JL; Ventura F
    Cells; 2019 Oct; 8(11):. PubMed ID: 31683698
    [No Abstract]   [Full Text] [Related]  

  • 24. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1.
    Kaplan FS; Xu M; Seemann P; Connor JM; Glaser DL; Carroll L; Delai P; Fastnacht-Urban E; Forman SJ; Gillessen-Kaesbach G; Hoover-Fong J; Köster B; Pauli RM; Reardon W; Zaidi SA; Zasloff M; Morhart R; Mundlos S; Groppe J; Shore EM
    Hum Mutat; 2009 Mar; 30(3):379-90. PubMed ID: 19085907
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Horizon of a Therapy for Rare Genetic Diseases: A "Druggable" Future for Fibrodysplasia Ossificans Progressiva.
    Cappato S; Giacopelli F; Ravazzolo R; Bocciardi R
    Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29587443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization.
    Shen Q; Little SC; Xu M; Haupt J; Ast C; Katagiri T; Mundlos S; Seemann P; Kaplan FS; Mullins MC; Shore EM
    J Clin Invest; 2009 Nov; 119(11):3462-72. PubMed ID: 19855136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutant activin-like kinase 2 in fibrodysplasia ossificans progressiva are activated via T203 by BMP type II receptors.
    Fujimoto M; Ohte S; Osawa K; Miyamoto A; Tsukamoto S; Mizuta T; Kokabu S; Suda N; Katagiri T
    Mol Endocrinol; 2015 Jan; 29(1):140-52. PubMed ID: 25354296
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fibrodysplasia ossificans progressiva mutant ACVR1 signals by multiple modalities in the developing zebrafish.
    Allen RS; Tajer B; Shore EM; Mullins MC
    Elife; 2020 Sep; 9():. PubMed ID: 32897189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ACVR1-Fc suppresses BMP signaling and chondro-osseous differentiation in an in vitro model of Fibrodysplasia ossificans progressiva.
    Pang J; Zuo Y; Chen Y; Song L; Zhu Q; Yu J; Shan C; Cai Z; Hao J; Kaplan FS; Shore EM; Zhang K
    Bone; 2016 Nov; 92():29-36. PubMed ID: 27492611
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans Progressiva.
    Srinivasan D; Arostegui M; Goebel EJ; Hart KN; Aykul S; Lees-Shepard JB; Idone V; Hatsell SJ; Economides AN
    Biomolecules; 2024 Jan; 14(1):. PubMed ID: 38254701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activin-A enhances mTOR signaling to promote aberrant chondrogenesis in fibrodysplasia ossificans progressiva.
    Hino K; Horigome K; Nishio M; Komura S; Nagata S; Zhao C; Jin Y; Kawakami K; Yamada Y; Ohta A; Toguchida J; Ikeya M
    J Clin Invest; 2017 Sep; 127(9):3339-3352. PubMed ID: 28758906
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Variable signaling activity by FOP ACVR1 mutations.
    Haupt J; Xu M; Shore EM
    Bone; 2018 Apr; 109():232-240. PubMed ID: 29097342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressiva.
    Chakkalakal SA; Zhang D; Culbert AL; Convente MR; Caron RJ; Wright AC; Maidment AD; Kaplan FS; Shore EM
    J Bone Miner Res; 2012 Aug; 27(8):1746-56. PubMed ID: 22508565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AAV-Mediated Targeting of the Activin A-ACVR1
    Yang YS; Lin C; Ma H; Xie J; Kaplan FS; Gao G; Shim JH
    Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BMPR2 inhibits activin and BMP signaling via wild-type ALK2.
    Olsen OE; Sankar M; Elsaadi S; Hella H; Buene G; Darvekar SR; Misund K; Katagiri T; Knaus P; Holien T
    J Cell Sci; 2018 Jun; 131(11):. PubMed ID: 29739878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activin A does not drive post-traumatic heterotopic ossification.
    Hwang C; Pagani CA; Das N; Marini S; Huber AK; Xie L; Jimenez J; Brydges S; Lim WK; Nannuru KC; Murphy AJ; Economides AN; Hatsell SJ; Levi B
    Bone; 2020 Sep; 138():115473. PubMed ID: 32553795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heterotopic bone induction via BMP signaling: Potential therapeutic targets for fibrodysplasia ossificans progressiva.
    Katagiri T; Tsukamoto S; Kuratani M
    Bone; 2018 Apr; 109():241-250. PubMed ID: 28754575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Constitutively active ALK2 receptor mutants require type II receptor cooperation.
    Bagarova J; Vonner AJ; Armstrong KA; Börgermann J; Lai CS; Deng DY; Beppu H; Alfano I; Filippakopoulos P; Morrell NW; Bullock AN; Knaus P; Mishina Y; Yu PB
    Mol Cell Biol; 2013 Jun; 33(12):2413-24. PubMed ID: 23572558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multi-system involvement in a severe variant of fibrodysplasia ossificans progressiva (ACVR1 c.772G>A; R258G): A report of two patients.
    Kaplan FS; Kobori JA; Orellana C; Calvo I; Rosello M; Martinez F; Lopez B; Xu M; Pignolo RJ; Shore EM; Groppe JC
    Am J Med Genet A; 2015 Oct; 167A(10):2265-71. PubMed ID: 26097044
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification.
    Culbert AL; Chakkalakal SA; Theosmy EG; Brennan TA; Kaplan FS; Shore EM
    Stem Cells; 2014 May; 32(5):1289-300. PubMed ID: 24449086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.